These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 20228646

  • 1. Refractory response to platelet transfusion therapy.
    Eisenberg S.
    J Infus Nurs; 2010; 33(2):89-97. PubMed ID: 20228646
    [Abstract] [Full Text] [Related]

  • 2. Platelet transfusion refractoriness.
    Hod E, Schwartz J.
    Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
    [Abstract] [Full Text] [Related]

  • 3. [Can thrombocyte crossmatching improve the efficiency of platelet transfusion?].
    Weisbach V, Zeiler T, Zingsem J, Musch R, Heuft HG, Eckstein R.
    Beitr Infusionsther; 1990 Jul; 26():160-2. PubMed ID: 1703820
    [Abstract] [Full Text] [Related]

  • 4. [Prevention of HLA-alloimmunization of recipients of platelet concentrates].
    Kuntz BM, Wollenhaupt HJ, Brüster HT.
    Beitr Infusionsther; 1991 Jul; 28():209-12. PubMed ID: 1725621
    [Abstract] [Full Text] [Related]

  • 5. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
    Sandler SG.
    Haematologia (Budap); 1998 Jul; 29(1):1-11. PubMed ID: 9704252
    [Abstract] [Full Text] [Related]

  • 6. New paradigms in the management of alloimmune refractoriness to platelet transfusions.
    Vassallo RR.
    Curr Opin Hematol; 2007 Nov; 14(6):655-63. PubMed ID: 17898571
    [Abstract] [Full Text] [Related]

  • 7. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
    Heal JM, Blumberg N, Masel D.
    Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
    [Abstract] [Full Text] [Related]

  • 8. Management of the Platelet Refractory Patient.
    Forest SK, Hod EA.
    Hematol Oncol Clin North Am; 2016 Jun; 30(3):665-77. PubMed ID: 27113003
    [Abstract] [Full Text] [Related]

  • 9. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A, Picard C.
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [Abstract] [Full Text] [Related]

  • 10. Strategies for managing refractoriness to platelet transfusions.
    Dan ME, Schiffer CA.
    Curr Hematol Rep; 2003 Mar; 2(2):158-64. PubMed ID: 12901147
    [Abstract] [Full Text] [Related]

  • 11. Management of patients refractory to platelet transfusion.
    Chockalingam P, Sacher RA.
    J Infus Nurs; 2007 Mar; 30(4):220-5. PubMed ID: 17667077
    [Abstract] [Full Text] [Related]

  • 12. [ABO blood groups and platelet transfusion].
    Eckstein R, Zeiler T, Zingsem J, Heuft HG, Musch R, Weisbach V.
    Beitr Infusionsther; 1990 Mar; 26():157-9. PubMed ID: 1703819
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Transfusion strategy: use of HLA-matched platelet transfusions for alloimmunized patients.
    Menitove JE, Duquesnoy RJ.
    Am J Med Technol; 1981 Feb; 47(2):114-20. PubMed ID: 7223758
    [Abstract] [Full Text] [Related]

  • 17. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y, Li W, Liu N, Zhang K, Gong Z, Li D, Wang L, Wang D, Jing Y, Wang J, Shan X.
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [Abstract] [Full Text] [Related]

  • 18. HLA-Mediated Platelet Refractoriness.
    Schmidt AE, Refaai MA, Coppage M.
    Am J Clin Pathol; 2019 Mar 01; 151(4):353-363. PubMed ID: 30285067
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.